These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22975372)
61. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Soleimani A; Berntsen A; Svane IM; Pedersen AE Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553 [TBL] [Abstract][Full Text] [Related]
62. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24 Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220 [TBL] [Abstract][Full Text] [Related]
63. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker]. Hazama S; Maeda K; Oka M Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395 [TBL] [Abstract][Full Text] [Related]
64. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF. Mier JW J Immunother; 2003; 26(2):95-6. PubMed ID: 12616100 [No Abstract] [Full Text] [Related]
65. 5T4 as a target for immunotherapy in renal cell carcinoma. Elkord E; Shablak A; Stern PL; Hawkins RE Expert Rev Anticancer Ther; 2009 Dec; 9(12):1705-9. PubMed ID: 19954280 [No Abstract] [Full Text] [Related]
66. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603 [TBL] [Abstract][Full Text] [Related]
72. Current immunotherapeutic strategies in renal cell carcinoma. Amato RJ Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554 [TBL] [Abstract][Full Text] [Related]
73. [III. Peptide vaccination therapy against brain tumors]. Hashimoto N; Kagawa N; Arita H; Tsuboi A; Oka Y; Oji Y; Sugiyama H; Yoshimine T Gan To Kagaku Ryoho; 2015 Jun; 42(6):687-9. PubMed ID: 26242006 [No Abstract] [Full Text] [Related]
74. Vaccination strategies in patients with renal cell carcinoma. Asemissen AM; Brossart P Cancer Immunol Immunother; 2009 Jul; 58(7):1169-74. PubMed ID: 19360405 [TBL] [Abstract][Full Text] [Related]
75. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report. Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798 [TBL] [Abstract][Full Text] [Related]
76. Peptide-based cancer vaccines. Machiels JP; van Baren N; Marchand M Semin Oncol; 2002 Oct; 29(5):494-502. PubMed ID: 12407514 [TBL] [Abstract][Full Text] [Related]
77. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases]. Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087 [TBL] [Abstract][Full Text] [Related]
78. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391 [TBL] [Abstract][Full Text] [Related]
79. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Carmichael MG; Benavides LC; Holmes JP; Gates JD; Mittendorf EA; Ponniah S; Peoples GE Cancer; 2010 Jan; 116(2):292-301. PubMed ID: 19924797 [TBL] [Abstract][Full Text] [Related]